AUXLY CANNABIS GROUP INC (XLY.CA) Stock Fundamental Analysis
TSX:XLY - Toronto Stock Exchange - CA05335P1099 - Common Stock - Currency: CAD
Taking everything into account, XLY scores 4 out of 10 in our fundamental rating. XLY was compared to 35 industry peers in the Pharmaceuticals industry. There are concerns on the financial health of XLY while its profitability can be described as average. XLY is growing strongly while it is still valued neutral. This is a good combination!
1. Profitability
1.1 Basic Checks
In the past year XLY was profitable.
XLY had a positive operating cash flow in the past year.
In the past 5 years XLY always reported negative net income.
The reported operating cash flow has been mixed in the past 5 years: XLY reported negative operating cash flow in multiple years.
1.2 Ratios
XLY's Return On Assets of 8.22% is amongst the best of the industry. XLY outperforms 97.14% of its industry peers.
XLY's Return On Equity of 16.98% is amongst the best of the industry. XLY outperforms 94.29% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.22% | ||
| ROE | 16.98% | ||
| ROIC | N/A |
ROA(3y)-20.84%
ROA(5y)-18.51%
ROE(3y)-81.82%
ROE(5y)-60.99%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
XLY's Profit Margin of 16.78% is amongst the best of the industry. XLY outperforms 91.43% of its industry peers.
Looking at the Gross Margin, with a value of 20.80%, XLY is doing worse than 71.43% of the companies in the same industry.
In the last couple of years the Gross Margin of XLY has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 16.78% | ||
| GM | 20.8% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.43%
GM growth 5YN/A
2. Health
2.1 Basic Checks
XLY does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for XLY has been increased compared to 1 year ago.
The number of shares outstanding for XLY has been increased compared to 5 years ago.
Compared to 1 year ago, XLY has an improved debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -1.73, we must say that XLY is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -1.73, XLY is doing worse than 65.71% of the companies in the same industry.
The Debt to FCF ratio of XLY is 3.54, which is a good value as it means it would take XLY, 3.54 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of XLY (3.54) is better than 82.86% of its industry peers.
A Debt/Equity ratio of 0.11 indicates that XLY is not too dependend on debt financing.
With a decent Debt to Equity ratio value of 0.11, XLY is doing good in the industry, outperforming 71.43% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.11 | ||
| Debt/FCF | 3.54 | ||
| Altman-Z | -1.73 |
ROIC/WACCN/A
WACC8.13%
2.3 Liquidity
XLY has a Current Ratio of 0.68. This is a bad value and indicates that XLY is not financially healthy enough and could expect problems in meeting its short term obligations.
The Current ratio of XLY (0.68) is worse than 88.57% of its industry peers.
A Quick Ratio of 0.34 indicates that XLY may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.34, XLY is doing worse than 82.86% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.68 | ||
| Quick Ratio | 0.34 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 121.83% over the past year.
The Revenue has grown by 26.78% in the past year. This is a very strong growth!
Measured over the past years, XLY shows a very strong growth in Revenue. The Revenue has been growing by 71.07% on average per year.
EPS 1Y (TTM)121.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%151.13%
Revenue 1Y (TTM)26.78%
Revenue growth 3Y13.43%
Revenue growth 5Y71.07%
Sales Q2Q%24.32%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
The Revenue is expected to grow by 22.57% on average over the next years. This is a very strong growth
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year18.98%
Revenue Next 2Y26.62%
Revenue Next 3Y26.12%
Revenue Next 5Y22.57%
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 9.50, the valuation of XLY can be described as very reasonable.
Based on the Price/Earnings ratio, XLY is valued cheaper than 91.43% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.92, XLY is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.5 | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Price/Free Cash Flow ratio, XLY is valued cheaper than 82.86% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 6.77 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for XLY!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX:XLY (6/27/2025, 7:00:00 PM)
0.095
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners0.01%
Inst Owner ChangeN/A
Ins Owners4.63%
Ins Owner ChangeN/A
Market Cap124.91M
Analysts45.71
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.5 | ||
| Fwd PE | N/A | ||
| P/S | 0.96 | ||
| P/FCF | 6.77 | ||
| P/OCF | 5.95 | ||
| P/B | 0.97 | ||
| P/tB | 1.26 | ||
| EV/EBITDA | N/A |
EPS(TTM)0.01
EY10.53%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.01
FCFY14.78%
OCF(TTM)0.02
OCFY16.8%
SpS0.1
BVpS0.1
TBVpS0.08
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.22% | ||
| ROE | 16.98% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | 16.78% | ||
| GM | 20.8% | ||
| FCFM | 14.22% |
ROA(3y)-20.84%
ROA(5y)-18.51%
ROE(3y)-81.82%
ROE(5y)-60.99%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.43%
GM growth 5YN/A
F-Score6
Asset Turnover0.49
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.11 | ||
| Debt/FCF | 3.54 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 24.46% | ||
| Cap/Sales | 1.95% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | 84.76% | ||
| Current Ratio | 0.68 | ||
| Quick Ratio | 0.34 | ||
| Altman-Z | -1.73 |
F-Score6
WACC8.13%
ROIC/WACCN/A
Cap/Depr(3y)27.93%
Cap/Depr(5y)61.49%
Cap/Sales(3y)4.52%
Cap/Sales(5y)11.68%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)121.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%151.13%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)26.78%
Revenue growth 3Y13.43%
Revenue growth 5Y71.07%
Sales Q2Q%24.32%
Revenue Next Year18.98%
Revenue Next 2Y26.62%
Revenue Next 3Y26.12%
Revenue Next 5Y22.57%
EBIT growth 1Y51.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year399.98%
EBIT Next 3Y106.86%
EBIT Next 5Y66%
FCF growth 1Y1625.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y171.42%
OCF growth 3YN/A
OCF growth 5YN/A